Continue Reading
Full article on CNBC
We're raising our price target on Eli Lilly as the GLP-1 leader delivers a huge beat
Market Intelligence Analysis
AI-Powered 90% GROQ-LLAMA-3.1-8B-INSTANT
Why This Matters
Eli Lilly's GLP-1 drugs have exceeded $1 billion in combined sales, with both Zepbound and Mounjaro showing triple-digit growth, leading to a raised price target.
Market Impact
Market impact analysis based on bullish sentiment with 90% confidence.
Sentiment
Bullish
AI Confidence
90%
Time Horizon
Short Term
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
Combined sales for the company's blockbuster GLP-1 drugs Zepbound and Mounjaro exceeded $1 billion, with each showing triple-digit growth.
AI Breakdown
Summary
Eli Lilly's GLP-1 drugs have exceeded $1 billion in combined sales, with both Zepbound and Mounjaro showing triple-digit growth, leading to a raised price target.
Market Impact
Market impact analysis based on bullish sentiment with 90% confidence.
Time Horizon
Short Term
Original article published by
CNBC
on February 4, 2026.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.